Skip to Content

Lorazepam

Class: Benzodiazepines
VA Class: CN302
CAS Number: 846-49-1
Brands: Ativan

Medically reviewed on November 20, 2017

Warning

    Concomitant Use with Opiates
  • Concomitant use of benzodiazepines and opiates may result in profound sedation, respiratory depression, coma, and death.700 701 703 705 706 707

  • Reserve concomitant use for patients in whom alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy and monitor closely for respiratory depression and sedation.700 703 (See Specific Drugs under Interactions.)

Introduction

Benzodiazepine; anticonvulsant, anxiolytic, and sedative.a b c d

Uses for Lorazepam

Anxiety Disorders

Management of anxiety disorders and short-term relief of anxiety or anxiety associated with depressive symptoms.a c

Preoperative Sedation, Anxiolysis, and Anterograde Amnesia

Preoperatively, to produce sedation, relieve anxiety, and provide anterograde amnesia.a d

Status Epilepticus

A drug of choice in the management of status epilepticus.435 543 545 546 a

Sedation in Critical-care Settings

Sedation of intubated and mechanically ventilated patients in a critical care setting.564 565 Other agents with more rapid onset (e.g., diazepam, midazolam) preferred for rapid sedation of acute agitated patients.564

Schizophrenia

Has been used in management of schizophrenia; may be helpful for management of anxiety, agitation, and sleep disturbances that are often present during the acute phase of schizophrenia in patients receiving antipsychotic therapy.529

May be helpful in patients experiencing akathisia while receiving antipsychotic drugs (e.g., for management of schizophrenia).529

Also has been used for treatment of acute catatonic reactions, whether associated with schizophrenia or other conditions.529

Cancer Chemotherapy-induced Nausea and Vomiting

Alone or as adjunctive therapy for the management of nausea and vomiting associated with emetogenic cancer chemotherapy (including cisplatin).492 493 494 495 496 497 498 499 500 501 502 503 504

Delirium

Management of delirium alone or in combination with an antipsychotic agent (e.g., haloperidol).533 535 536 537

Drug-induced Cardiovascular Emergencies

Adjunct in the management of certain drug-induced cardiovascular emergencies.696 May be beneficial adjunctively in patients with cocaine-induced acute coronary syndrome.696

Lorazepam Dosage and Administration

General

  • Use smallest effective dosage to avoid oversedation.a b

  • In patients who have received prolonged (e.g., for several months) therapy, avoid abrupt discontinuance, since manifestations of withdrawal can be precipitated; gradually taper dosage.a

Administration

Administer orally, IM, or by IV injection or continuous infusion.a b c d Avoid intra-arterial injection (arteriospasm may cause gangrene, possibly requiring amputation).a d

Oral Administration

Dilute dose of oral concentrate solution in 30 mL or more of diluent (e.g., water, juice, carbonated or soda-like beverages) or mix with semi-solid foods (e.g., applesauce, pudding) just prior to administration.a

IM Administration

Administer undiluted injection deeply into a large muscle mass.435 IM administration is not usually recommended, but may be used if IV access is not available.435

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Direct injection should be made with repeated aspiration to ensure that none of the drug is injected intra-arterially and that perivascular extravasation does not occur.a d If pain occurs during the injection, immediately stop the injection and determine whether intra-arterial injection or extravasation has occurred.d

Equipment necessary to maintain a patent airway and to support respiration and ventilation should be immediately available prior to IV administration.435 Monitor vital signs during IV infusion of the drug.435

Dilution

For administration as a direct injection, dilute 2-mg/mL injection with an equal volume of compatible diluent (e.g., sterile water for injection, 0.9% sodium chloride injection, or 5% dextrose injection) immediately prior to IV administration.a d

For administration as a continuous infusion, dilute the 2-mg/mL injection in a glass container to a concentration of ≤1 mg/mL with a compatible IV fluid.564 (See Solution Compatibility under Stability.)

Alternatively, 2-mg/mL injection may be administered undiluted as an infusion using a patient-controlled analgesia (PCA) device.564

Rate of Administration

Administer by direct injection into a vein or the tubing of a free-flowing compatible IV infusion at a rate ≤2 mg/minute.a (See Solution Compatibility under Stability.)

Dosage

Pediatric Patients

Status Epilepticus
IV

Initially, 0.05–0.1 mg/kg.543 546

Sedation in Critical-care Settings
IV

Children ≤12 years of age: Dosages of 0.025–0.05 mg/kg (up to 2 mg as initial dose) every 2–4 hours have been used.565 Alternatively, 0.025 mg/kg per hour (up to 2 mg/hour) as a continuous infusion; titrate infusion rate as necessary or supplement with rapid injections of the drug to provide the desired level of sedation.565 Children <2 months of age: Reduce initial dose by 50% because of wide interpatient variations in dosage requirements and low hepatic metabolic function.565

Children >12 years of age: 0.02–0.06 mg/kg given every 2–6 hours.564 Alternatively, 0.01–0.1 mg/kg per hour as a continuous infusion; titrate infusion rate to the lowest dosage that provides desired level of sedation.564

Adults

Anxiety
Oral

Initially, 2–3 mg daily divided in 2 or 3 doses.a c Maintenance dosage of 1–10 mg daily (usually 2–6 mg) in divided doses, with the largest dose administered at bedtime.a c Increase dosage gradually if higher dosage is indicated; increase the evening dose before the daytime doses.a

For insomnia caused by anxiety, 2–4 mg as a single daily dose at bedtime.a c

Preoperative Sedation, Anxiolysis, and Anterograde Amnesia
IM

0.05 mg/kg (up to 4 mg) at least 2 hours prior to surgery.a d

IV

Initially, 0.044 mg/kg (up to 2 mg) 15–20 minutes prior to surgery; do not routinely exceed this dosage in patients >50 years of age.a d For amnesic effects, doses up to 0.05 mg/kg (maximum 4 mg) may be administered.a d

Status Epilepticus
IV

Initially, 4 mg.435 If seizures continue or recur after a 10- to 15-minute observation period, administer an additional 4-mg dose.435 Manufacturer states that experience with administration of additional doses is limited.435

Sedation in Critical-care Settings
IV

0.02–0.06 mg/kg given every 2–6 hours.564

Alternatively, 0.01–0.1 mg/kg per hour as a continuous infusion; titrate infusion rate to the lowest dosage that provides desired level of sedation.564

Cancer Chemotherapy-induced Nausea and Vomiting
Oral

2.5 mg the evening before and just after initiation of chemotherapy.496

IV

1.5 mg/m2 (up to 3 mg) over 5 minutes, given 45 minutes before administration of chemotherapy.a

Delirium
IV

0.5–1 mg, immediately following 3 mg of haloperidol.533

Prescribing Limits

Adults

Preoperative Sedation, Anxiolysis, and Anterograde Amnesia
IM

4 mg.a d

IV

2 mg for sedation and relief of anxiety.a d For amnesic effects, 4 mg;a d 3 mg for management of chemotherapy-induced nausea and vomiting.a

Special Populations

Hepatic Impairment

Dosage adjustments are not required for parenteral administration.435

Adjust oral dosage carefully in patients with severe hepatic insufficiency because oral therapy may exacerbate hepatic encephalopathy; lower than recommended dosages may be sufficient in these patients.283

Renal Impairment

Dosage adjustment is not required for single doses of lorazepam injection; however, exercise caution with administration of multiple doses over a short period of time.435

Geriatric Patients

Cautious dosage selection recommended because of greater sensitivity and possible age-related decreases in hepatic or renal function; initiate therapy at the lower end of the usual range.283 435

Anxiety Disorders

Oral: Initially, 1–2 mg daily divided in 2 or 3 doses.a

Preoperative Sedation, Anxiolysis, and Anterograde Amnesia

IM or IV: Patients >50 years of age generally should not receive initial dose >2 mg unless enhanced suppression of recall is desired.a d Excessive and prolonged sedation may occur.435

Cautions for Lorazepam

Contraindications

  • Known hypersensitivity to benzodiazepines or any ingredient in the formulation (e.g., benzyl alcohol, polyethylene glycol, or propylene glycol in the injection).283 435

  • Acute angle-closure glaucoma (but may be administered to patients with open-angle glaucoma who are receiving appropriate therapy);c d 283 435 however, clinical rationale for this contraindication has been questioned.b

  • Injection contraindicated in patients with sleep apnea.435

  • Injection contraindicated in patients with severe respiratory insufficiency, except in those patients receiving mechanical ventilation requiring relief of anxiety and/or diminished recall of events.435

Warnings/Precautions

Warnings

Concomitant Use with Opiates

Concomitant use of benzodiazepines, including lorazepam, and opiates may result in profound sedation, respiratory depression, coma, and death.700 701 703 705 706 707 Substantial proportion of fatal opiate overdoses involve concurrent benzodiazepine use.700 701 705 706 707 711

Reserve concomitant use of lorazepam and opiates for patients in whom alternative treatment options are inadequate.700 703 (See Specific Drugs under Interactions.)

Respiratory and Cardiovascular Effects

Use oral lorazepam with caution in patients with compromised respiratory function (e.g., chronic pulmonary insufficiency, sleep apnea).b c

Possible apnea, hypotension, bradycardia, or cardiac arrest with parenteral administration, particularly in geriatric or severely ill patients, in patients with limited pulmonary reserve or unstable cardiovascular status, or if the drug is administered IV too rapidly.b 566 567

Concomitant use of other CNS depressants may increase the risk of apnea.a c

Administer IV only in settings in which continuous monitoring of respiratory and cardiac function (i.e., pulse oximetry) is possible.435 Monitoring of vital signs should continue during recovery period.435 566 567

Facilities, age- and size-appropriate equipment for bag/mask/valve ventilation and intubation, drugs, and skilled personnel necessary for ventilation and intubation, administration of oxygen, assisted or controlled respiration, airway management, and cardiovascular support should be immediately available when lorazepam is administered IV.435 566 567 d

Status Epilepticus

Should be used for the treatment of status epilepticus only by clinicians experienced in the comprehensive management of the disease.435

Careful monitoring of respiratory rate and maintenance of an adequate, patent airway is required; ventilatory support may be necessary.435

Because of the prolonged duration of action, sedative effects of lorazepam (especially after multiple doses) may increase impairment of consciousness observed in the postictal state.435

CNS Effects

Performance of activities requiring mental alertness and physical coordination (operating machinery, driving a motor vehicle) may be impaired.a b c Impairment may persist for 24–48 hours following parenteral administration.a d Premature ambulation may result in falls.d

Concurrent use of other CNS depressants may cause additive or potentiated CNS depression.a b c d (See Concomitant Use with Opiates under Cautions and also see Specific Drugs under Interactions.)

May interfere with assessment of level of anesthesia when administered IV prior to regional or local anesthesia, especially when given at doses >0.5 mg/kg or when opiate agonists or partial agonists are used concomitantly with recommended lorazepam doses.a d

Psychiatric Indications

Do not use in patients with depressive neuroses or psychotic reactions in which anxiety is not prominent.a c

Abuse Potential

Possible tolerance, psychologic dependence, and physical dependence following prolonged administration.283 b

Patients with a history of drug or alcohol dependence or abuse are at risk of habituation or dependence; use only with careful surveillance in such patients.b c

Withdrawal

Symptoms of withdrawal (similar to barbiturates or alcohol) may occur if discontinued abruptly.a c Symptoms may be relieved by tapering the dosage.a c

Endoscopic Procedures

Insufficient data to support use for outpatient endoscopic procedures; when used for inpatient endoscopic procedures, adequate recovery room observations required.d

General Precautions

Suicide

Possibility of suicide in depressed patients; prescribe drug in the smallest feasible quantity.b c

Paradoxical Reactions

Paradoxical reactions (e.g., anxiety, excitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, hallucinations) may occur, particularly in children and geriatric patients.b c Discontinue drug if such reactions occur.b c

Propylene Glycol or Polyethylene Glycol Toxicity

Possible adverse effects associated with propylene glycol (e.g., lactic acidosis, hyperosmolality, hypotension) or polyethylene glycol (e.g., acute tubular necrosis) in patients receiving higher than recommended parenteral dosages.435 More likely to occur in patients with renal impairment.435

Specific Populations

Pregnancy

Category D.d

Based on animal data, repeated or prolonged use of general anesthetics and sedation drugs, including lorazepam, during the third trimester of pregnancy may result in adverse neurodevelopmental effects in the fetus.750 753 (See Pediatric Use under Cautions and also see Advice to Patients.)

Lactation

Distributed into milk.d

Administer orally to nursing women only if the potential benefits to the woman outweigh the possible risk to the infant.283 Monitor nursing infants for adverse effects (e.g., sedation, irritability).283

Do not administer lorazepam injection to nursing women, because of possible adverse effects (e.g., sedation).435

Pediatric Use

Safety and efficacy of tablets and oral concentrate solution not established in children <12 years of age.283

Safety of the injection for treatment of status epilepticus or efficacy for preoperative sedation not established in children <18 years of age.435

Paradoxical excitation (e.g., tremors, agitation, euphoria, logorrhea, brief episodes of visual hallucinations) reported in 10–30% of children <8 years of age.435

Seizures and myoclonus reported in pediatric patients, especially low birth weight neonates, receiving lorazepam injection.435 Brief tonic-clonic seizures reported in children receiving lorazepam for the management of atypical petit mal status epilepticus.435

Repeated or prolonged use of general anesthetics and sedation drugs, including lorazepam, in children <3 years of age or during the third trimester of pregnancy may adversely affect neurodevelopment.750 753 In animals, use for >3 hours of anesthetic and sedation drugs that block N-methyl-d-aspartic acid (NMDA) receptors and/or potentiate GABA activity leads to widespread neuronal apoptosis in the brain and long-term deficits in cognition and behavior;750 751 752 753 clinical relevance to humans is unknown.750 Some evidence suggests similar deficits may occur in children following repeated or prolonged exposure to anesthesia early in life.750 752 Some evidence also indicates that a single, relatively brief exposure to general anesthesia in generally healthy children is unlikely to cause clinically detectable deficits in global cognitive function or serious behavioral disorders.750 751 752 Most studies to date have substantial limitations; further research needed to fully characterize effects, particularly for prolonged or repeated exposures and in more vulnerable populations (e.g., less healthy children).750 Consider benefits and potential risks when determining the timing of elective procedures requiring anesthesia.750 FDA states that medically necessary procedures should not be delayed or avoided.750 753 (See Advice to Patients.)

Some pediatric patients (premature and low-birth weight infants or those receiving high doses of the injection) may be susceptible to adverse effects associated with benzyl alcohol, polyethylene glycol, and propylene glycol.435 Large amounts of benzyl alcohol (i.e., 100–400 mg/kg daily) have been associated with toxicity in neonates;435 584 585 586 587 588 589 590 each mL of lorazepam injection contains 2 mg of benzyl alcohol.d (See Propylene Glycol or Polyethylene Glycol Toxicity under Cautions.)

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.283 435 Possibility of greater sensitivity to the drug (e.g., respiratory or CNS depression) in some geriatric individuals.d

Select initial dosages at the lower end of the usual range because of potential for greater sensitivity and age-related decreases in hepatic or renal function.283 435 (See Geriatric Patients under Dosage and Administration.)

May cause excessive sedation for 6–8 hours or longer after surgery in this population.435

Possible paradoxical excitation (e.g., anxiety, excitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, hallucinations).b c

Hepatic Impairment

Lorazepam injection is not recommended for use in patients with hepatic failure; may be used in patients with mild to moderately severe hepatic disease.d (See Hepatic Impairment under Dosage and Administration.)

Oral lorazepam may exacerbate hepatic encephalopathy; therefore, use with caution in patients with severe hepatic insufficiency and/or encephalopathy.283

Renal Impairment

Lorazepam injection is not recommended for use in renal failure; use with caution in patients with mild to moderate renal disease.a d (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

With oral therapy, sedation, dizziness, weakness, unsteadiness.c

With parenteral therapy for the management of status epilepticus, hypotension, somnolence, respiratory failure; with parenteral therapy for preoperative use, excessive sleepiness, drowsiness.d

Interactions for Lorazepam

Specific Drugs

Drug

Interaction

Comments

Cimetidine

Effect on lorazepam pharmacokinetics unlikelyd

No dosage adjustment of lorazepam requiredd

Disulfiram

Effect on lorazepam pharmacokinetics unlikelyd

No dosage adjustment of lorazepam requiredd

Clozapine

Marked sedation, excessive salivation, ataxia, and, rarely, death reportedc d

Use with cautionc d

CNS depressants (e.g., barbiturates, sedatives, anticonvulsants, alcohol)

Additive CNS effectsc d

Use with caution to avoid overdosagec d

Avoid alcohol use700

Contraceptives, oral

Possible increased clearance of parenteral lorazepamd

Dosage of parenteral lorazepam may need to be increased d

Haloperidol

Apnea, coma, bradycardia, arrhythmia, heart arrest, and death reportedd

Use with cautiond

Loxapine

Respiratory depression, stupor, and/or hypotension reported rarelyd

Use with cautiond

Metoprolol

Effect on lorazepam pharmacokinetics unlikelyd

No dosage adjustment of lorazepam requiredd

Metronidazole

Effect on lorazepam pharmacokinetics unlikelyd

No dosage adjustment of lorazepam requiredd

Opiate agonists and partial agonists

Risk of profound sedation, respiratory depression, coma, or death700 701 703 705 706 707

Whenever possible, avoid concomitant use708 709 710 711

Opiate analgesics: Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy; monitor closely for respiratory depression and sedation700 703

In patients receiving lorazepam, initiate opiate analgesic, if required, at reduced dosage and titrate based on clinical response700

In patients receiving an opiate analgesic, initiate lorazepam, if required for any indication other than epilepsy, at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response700

Opiate antitussives: Avoid concomitant use700 704

Consider offering naloxone to patients receiving benzodiazepines and opiates concomitantly709 712

Probenecid

Decreased lorazepam clearancec d

Reduce lorazepam dosage by 50%c d

Propranolol

Effect on lorazepam pharmacokinetics unlikelyd

No dosage adjustment of lorazepam requiredd

Ranitidine

Effect on lorazepam pharmacokinetics unlikelyd

No dosage adjustment of lorazepam requiredd

Scopolamine

Possible increased sedation, hallucinations, and irrational behaviord

No additional benefit from the combinationd

Theophylline

Decreased sedative effectsd

Valproate

Increased plasma lorazepam concentrationd

Reduce usual lorazepam dosage by 50%d

Lorazepam Pharmacokinetics

Absorption

Bioavailability

Readily absorbed from the GI tract following oral administration; absolute bioavailability is 90%.c

Completely and rapidly absorbed following IM administration.d

Peak plasma concentrations are attained in approximately 2 hours following oral administrationc and within 3 hours following IM administration.d

Onset

After IV administration, the onset of anticonvulsant, anxiolytic, or sedative action occurs in 1–5 minutes.b

After IM administration, the onset of action is 15–30 minutes.b

Duration

After IV or IM administration, the duration of anticonvulsant, anxiolytic, or sedative action is 12–24 hours.b

Distribution

Extent

Widely distributed into body tissues; crosses the blood-brain barrier.b d

Crosses the placenta and is distributed into milk.b d

Plasma Protein Binding

Approximately 85–91%.b c d

Elimination

Metabolism

Extensively metabolized in the liver to inactive metabolites.c d

Elimination Route

Excreted principally in urine as metabolites.c d

Half-life

10–20 hours.b c d

Special Populations

In neonates, clearance reduced by 80% compared with healthy adults.d

In geriatric patients or patients with hepatic cirrhosis, clearance not substantially altered.b d

In patients with renal impairment, clearance of lorazepam glucuronide is reduced, but total clearance of lorazepam is not altered following single IV dose.d

Stability

Storage

Oral

Tablets

Tight containers at 20–25°C.c

Concentrate Solution

2–8°C; protect from light.a

Parenteral

Injection

2–8°C; protect from light.d

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution CompatibilityHID

Variable

Dextrose 5% in water

Ringer’s injection, lactated

Sodium chloride 0.9%

Drug Compatibility
Admixture CompatibilityHID

Incompatible

Dexamethasone sodium phosphate with diphenhydramine HCl and metoclopramide HCl

Y-Site CompatibilityHID

Compatible

Acyclovir sodium

Albumin human

Allopurinol sodium

Amifostine

Amikacin sulfate

Amiodarone HCl

Amphotericin B cholesteryl sulfate complex

Anakinra

Atracurium besylate

Bivalirudin

Bumetanide

Caspofungin acetate

Cefotaxime sodium

Ceftaroline fosamil

Ciprofloxacin

Cisatracurium besylate

Cladribine

Clonidine HCl

Co-trimoxazole

Dexamethasone sodium phosphate

Dexmedetomidine HCl

Diltiazem HCl

Dobutamine HCl

Docetaxel

Dopamine HCl

Doripenem

Doxorubicin HCl liposome injection

Epinephrine HCl

Erythromycin lactobionate

Etomidate

Etoposide phosphate

Famotidine

Fenoldopam mesylate

Fentanyl citrate

Filgrastim

Fluconazole

Fludarabine phosphate

Fosphenytoin sodium

Furosemide

Gemcitabine HCl

Gentamicin sulfate

Granisetron HCl

Haloperidol lactate

Heparin sodium

Hetastarch in lactated electrolyte injection (Hextend)

Hydrocortisone sodium succinate

Hydromorphone HCl

Labetalol HCl

Levofloxacin

Linezolid

Melphalan HCl

Methadone HCl

Metronidazole

Micafungin sodium

Midazolam HCl

Milrinone lactate

Morphine sulfate

Nicardipine HCl

Nitroglycerin

Norepinephrine bitartrate

Oxaliplatin

Paclitaxel

Palonosetron HCl

Pancuronium bromide

Pemetrexed disodium

Piperacillin sodium–tazobactam sodium

Potassium chloride

Propofol

Ranitidine HCl

Remifentanil HCl

Tacrolimus

Teniposide

Thiotepa

Vancomycin HCl

Vecuronium bromide

Vinorelbine tartrate

Zidovudine

Incompatible

Aldesleukin

Aztreonam

Gallium nitrate

Idarubicin HCl

Imipenem–cilastatin sodium

Omeprazole sodium

Ondansetron HCl

Sargramostim

Variable

Foscarnet sodium

Actions

  • Effects appear to be mediated through the inhibitory neurotransmitter GABA; the site and mechanism of action within the CNS appear to involve a macromolecular complex (GABAA-receptor-chloride ionophore complex) that includes GABAA receptors, high-affinity benzodiazepine receptors, and chloride channels.320 358 359 360 361 362 363 364 365 366 367 368 369 370

Advice to Patients

  • Risk of potentially fatal additive effects (e.g., profound sedation, respiratory depression, coma) if used concomitantly with opiates either therapeutically or illicitly.700 703 Avoid concomitant use of opiate antitussives;700 704 also avoid concomitant use of opiate analgesics unless use is supervised by clinician.700 703

  • Potential for drug to impair mental alertness or physical coordination; avoid driving or operating machinery until effects on individual are known.c d Following parenteral dose, wait 24–48 hours or until drowsiness subsides before participating in such activities.d

  • Importance of informing patients of the pharmacologic effects of lorazepam (e.g., sedation, relief of anxiety, lack of recall) and the duration of these effects (≥8 hours) so that they may understand the risks and benefits.c d

  • Importance of avoiding premature ambulation (within 8 hours of dose) in patients receiving parenteral lorazepam.a d

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.c Importance of avoiding alcohol-containing beverages or products (for at least 24–48 hours after parenteral administration).b d

  • When procedures requiring general anesthetics or sedation drugs, including lorazepam, are considered for young children or pregnant women, importance of discussing with the patient, parent, or caregiver the benefits, risks (including potential risk of adverse neurodevelopmental effects), and appropriate timing and duration of the procedure.750 753

  • Importance of informing clinicians about any concomitant illnesses (e.g., depression, respiratory disorders).c

  • Importance of taking only as prescribed; do not increase dosage or duration of therapy unless otherwise instructed by a clinician.c

  • Importance of not abruptly discontinuing therapy; consult clinician about discontinuing use.c

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.c d

  • Importance of informing patients of other important precautionary information.c d (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

Lorazepam is subject to control under the Federal Controlled Substances Act of 1970 as a schedule IV (C-IV) drug.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

LORazepam

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

For solution, concentrate

2 mg/mL*

LORazepam Solution Concentrate (C-IV)

Tablets

0.5 mg*

Ativan (C-IV)

Valeant

1 mg*

Ativan (C-IV; scored)

Valeant

2 mg*

Ativan (C-IV; scored)

Valeant

Parenteral

Injection

2 mg/mL*

Ativan (C-IV)

West-Ward

LORazepam Injection (C-IV)

4 mg/mL*

Ativan (C-IV)

West-Ward

LORazepam Injection (C-IV)

AHFS DI Essentials. © Copyright 2018, Selected Revisions November 20, 2017. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

283. Wyeth Laboratories Inc. Ativan (lorazepam) tablets prescribing information. Philadelphia, PA; 2002 Oct.

320. Rall TW. Hypnotics and sedatives; ethanol: benzodiazepines and management of insomnia. In: Gilman AG, Rall TW, Nies AS et al. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:346-58,369-70.

358. Bloom FE. Neurohumoral transmission and the central nervous system: amino acids. In: Gilman AG, Rall TW, Nies AS et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:256-8.

359. Haefely W. The GABA-benzodiazepine interaction fifteen years later. Neurochem Res. 1990; 15:169-74. http://www.ncbi.nlm.nih.gov/pubmed/2159122?dopt=AbstractPlus

360. De Feudis FV. Overview—GABAa receptors. Ann NY Acad Sci. 1990; 585:231-40. http://www.ncbi.nlm.nih.gov/pubmed/2162643?dopt=AbstractPlus

361. Mohler H, Malherbe P, Draguhn A et al. GABAa-receptors: structural requirements and sites of gene expression in mammalian brain. Neurochem Res. 1990; 15:199-207. http://www.ncbi.nlm.nih.gov/pubmed/2159125?dopt=AbstractPlus

362. Farrant M, Gibbs TT, Farb DH. Molecular and cellular mechanisms of GABA/benzodiazepine-receptor regulation: electrophysiological and biochemical studies. Neurochem Res. 1990; 15:175-91. http://www.ncbi.nlm.nih.gov/pubmed/2159123?dopt=AbstractPlus

363. Sieghart W. Benzodiazepine receptor subtypes and their possible clinical significance. Psychopharmacol Ser. 1989; 7:131-7. http://www.ncbi.nlm.nih.gov/pubmed/2574448?dopt=AbstractPlus

364. Knapp RJ, Malatynska E, Yamamura HI. From binding studies to the molecular biology of GABA receptors. Neurochem Res. 1990; 15:105-12. http://www.ncbi.nlm.nih.gov/pubmed/2159117?dopt=AbstractPlus

365. Williams M. Anxioselective anxiolytics. J Med Chem. 1983; 26:619-28. http://www.ncbi.nlm.nih.gov/pubmed/6132997?dopt=AbstractPlus

366. Rogawski MA, Porter RJ. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev. 1990; 42:223-86. http://www.ncbi.nlm.nih.gov/pubmed/2217531?dopt=AbstractPlus

367. Haefely WE. Pharmacology of the benzodiazepine receptor. Eur Arch Psychiatry Neurol Sci. 1989; 238:294-301. http://www.ncbi.nlm.nih.gov/pubmed/2569974?dopt=AbstractPlus

368. Haefely WE. Benzodiazepines. Int Anesthesiol Clin. 1988; 26:262-72. http://www.ncbi.nlm.nih.gov/pubmed/2461909?dopt=AbstractPlus

369. Schoch P, Richards JG, Haring P et al. Co-localization of GABA receptors and benzodiazepine receptors in the brain shown by monoclonal antibodies. Nature. 1985; 314:168-71. http://www.ncbi.nlm.nih.gov/pubmed/2983231?dopt=AbstractPlus

370. Haefely W. Endogenous ligands of the benzodiazepine receptor. Pharmacopsychiatry. 1988; 21:43-6. http://www.ncbi.nlm.nih.gov/pubmed/2834760?dopt=AbstractPlus

435. Wyeth Laboratories. Ativan (lorazepam) injection prescribing information. Philadelphia, PA; 2002 Oct.

492. Kris MG, Pisters KM, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer. 1994; 2:297-300. http://www.ncbi.nlm.nih.gov/pubmed/8000726?dopt=AbstractPlus

493. Gralla RJ. Adverse effects of treatment: antiemetic therapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. 4th ed. Philadelphia: J.B. Lippincott Company; 1993:2338-48.

494. Malik IA, Khan WA, Qazilbash M et al. Clinical efficacy of lorazepam in prophylaxis of anticipatory, acute, and delayed nausea and vomiting induced by high doses of cisplatin. A prospective randomized trial. Am J Clin Oncol. 1995; 18:170-5. http://www.ncbi.nlm.nih.gov/pubmed/7900711?dopt=AbstractPlus

495. Ahn MJ, Lee JS, Lee KH et al. A randomized double-blind trial of ondansetron alone versus in combination with dexamethasone versus in combination with dexamethasone and lorazepam in the prevention of emesis due to cisplatin-based chemotherapy. Am J Clin Oncol. 1994; 17:150-6. http://www.ncbi.nlm.nih.gov/pubmed/8141107?dopt=AbstractPlus

496. Clerico M, Bertetto O, Cardinali C et al. Antiemetic activity of lorazepam in the prophylactic treatment of vomiting induced by cisplatin: a double-blind placebo controlled study with cross-over design. Ann Oncol. 1992; 3(Suppl 5):188.

497. Grunberg SM, Hesketh PJ. Control of chemotherapy-induced emesis. N Engl J Med. 1993; 329:1790. http://www.ncbi.nlm.nih.gov/pubmed/8232489?dopt=AbstractPlus

498. Triozzi PL, Laszlo J. Optimum management of nausea and vomiting in cancer chemotherapy. Drugs. 1987; 136-49.

499. Baltzer L, Kris MG, Tyson LB et al. The addition of ondansetron to the combination of metoclopramide, dexamethasone, and lorazepam did not improve vomiting prevention in patients receiving high-dose cisplatin. Cancer. 1994; 73:720-3. http://www.ncbi.nlm.nih.gov/pubmed/8299095?dopt=AbstractPlus

500. Kris MG, Tyson LB, Clark RA et al. Oral ondansetron for the control of delayed emesis after cisplatin. Cancer. 1992; 70:1012-6. http://www.ncbi.nlm.nih.gov/pubmed/1386282?dopt=AbstractPlus

501. Kris MG, Gralla RJ, Clark RA et al. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. Cancer. 1987; 60:2816-22. http://www.ncbi.nlm.nih.gov/pubmed/3315176?dopt=AbstractPlus

502. Kris MG, Gralla RJ, Clark RA et al. Consecutive dose-finding trials adding lorazepam to the combination of metoclopramide plus dexamethasone: improved subjective effectiveness over the combination of diphenhydramine plus metoclopramide plus dexamethasone. Cancer Treat Rep. 1985; 69:1257-62. http://www.ncbi.nlm.nih.gov/pubmed/3912039?dopt=AbstractPlus

503. Kris MG, Baltzer L, Pisters KMW et al. Enhancing the effectiveness of the specific serotonin antagonists. Cancer. 1993; 72:3436-42. http://www.ncbi.nlm.nih.gov/pubmed/8242576?dopt=AbstractPlus

504. Mitchelson F. Pharmacological agents affecting emesis: a review (part I). Drugs. 1992; 43:295-315. http://www.ncbi.nlm.nih.gov/pubmed/1374316?dopt=AbstractPlus

529. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161(2 Suppl):1-56.

533. Trzepacz P, Breitbart W, Levenson J et al for the American Psychiatric Association Working Group on Delirium. Practice guideline for the treatment of patients with delirium. Am J Psychiatry. 1999; 156(Suppl 5):1-20.

535. Fernandez F, Levy JK, Mansell PWA. Management of delirium in terminally ill AIDS patients. Int J Psychiatry Med. 1989; 19:165-72. http://www.ncbi.nlm.nih.gov/pubmed/2681028?dopt=AbstractPlus

536. Adams F, Fernandez F, Andersson BS. Emergency pharmacotherapy of delirium in the critically ill cancer patient. Psychosomatics. 1986; 27(Supp 1):33-8. http://www.ncbi.nlm.nih.gov/pubmed/3952253?dopt=AbstractPlus

537. Menza MA, Murray GB, Holmes VF. Controlled study of extrapyramidal reactions in the management of delirious medically ill patients: intravenous haloperidol versus intravenous heloperidol plus benzodiazepines. Heart Lung. 1988; 17:238-41. http://www.ncbi.nlm.nih.gov/pubmed/2896642?dopt=AbstractPlus

543. Dodson WE. Special pharmacokinetic considerations in children Epilepsia. 1987; (28 Suppl 1):56-70. (IDIS 316902)

545. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998; 338:970-6. http://www.ncbi.nlm.nih.gov/pubmed/9521986?dopt=AbstractPlus

546. American Academy of Pediatrics Committee on Drugs. Drugs for pediatric emergencies. Pediatrics. 1998; 101:1-11. http://www.ncbi.nlm.nih.gov/pubmed/9417143?dopt=AbstractPlus

564. Task Force of the American College of Critical Care Medicine (ACCM) in collaboration with the American Society of Health-System Pharmacists (ASHP) and in alliance with the American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Am J Health-Syst Pharm. 2002; 59:150-78. http://www.ncbi.nlm.nih.gov/pubmed/11826570?dopt=AbstractPlus

565. Tobias JD. Sedation analgesia in paediatric intensive care units. Pediatric Drugs. 1999; 1:109-26. http://www.ncbi.nlm.nih.gov/pubmed/10937446?dopt=AbstractPlus

566. American Academy of Pediatrics, Committee on Drugs. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures. Pediatrics. 1992;89:1110-1115.

567. American Academy of Pediatrics, Committee on Drugs. Guidelines for monitoring and management of pediatric patients during and after sedation for diagnostic and therapeutic procedures: addendum. Pediatrics. 2002;110:836-8.

584. American Academy of Pediatrics Committee on Fetus and Newborn and Committee on Drugs. Benzyl alcohol: toxic agent in neonatal units. Pediatrics. 1983; 72:356-8. (IDIS 175725)

585. Anon. Benzyl alcohol may be toxic to newborns. FDA Drug Bull. 1982; 12(2):10-1.

586. Anon. Neonatal deaths associated with use of benzyl alcohol--United States. MMWR. 1982; 31:290-1.

587. Gershanik J, Boecler B, Ensley H et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med. 1982; 307:1384-8.

588. Menon PA, Thach BT, Smith CH et al. Benzyl alcohol toxicity in a neonatal intensive care unit: incidence, symptomatology, and mortality. Am J Perinatol. 1984; 1:288-92.

589. Anderson CW, Ng KJ, Andresen B et al. Benzyl alcohol poisoning in a premature newborn infant. Am J Obstet Gynecol. 1984; 148:344-6.

590. Food and Drug Administration. Parenteral drug products containing benzyl alcohol or other antimicrobial preservatives; intent and request for information. [Docet No. 85N-0043] Fed Regist. 1985; 50:20233-5.

696. Vanden Hoek TL, Morrison LJ, Shuster M et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010; 122(18 Suppl 3):S829-61.

700. US Food and Drug Administration. Drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Silver Spring, MD; 2016 Aug 31. From FDA website. https://www.fda.gov/drugs/drugsafety/ucm518473.htm

701. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309:657-9. http://www.ncbi.nlm.nih.gov/pubmed/23423407?dopt=AbstractPlus

703. Hughes A. Letter to manufacturers of benzodiazepines: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM518615.pdf

704. Seymour S. Letter to manufacturers of opioid antitussives: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM518612.pdf

705. Park TW, Saitz R, Ganoczy D et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015; 350:h2698. http://www.ncbi.nlm.nih.gov/pubmed/26063215?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=4462713&blobtype=pdf

706. Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015; 49:493-501. http://www.ncbi.nlm.nih.gov/pubmed/26143953?dopt=AbstractPlus

707. Dasgupta N, Funk MJ, Proescholdbell S et al. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. Pain Med. 2016; 17:85-98. http://www.ncbi.nlm.nih.gov/pubmed/26333030?dopt=AbstractPlus

708. Nuckols TK, Anderson L, Popescu I et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014; 160:38-47. http://www.ncbi.nlm.nih.gov/pubmed/24217469?dopt=AbstractPlus

709. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016; 65:1-49. http://www.ncbi.nlm.nih.gov/pubmed/26987082?dopt=AbstractPlus

710. Manchikanti L, Abdi S, Atluri S et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. Pain Physician. 2012; 15(3 Suppl):S67-116.

711. New York City Department of Health and Mental Hygiene. New York City emergency department discharge opioid prescribing guidelines. From NYC Health website. 2013 Jan. http://www1.nyc.gov/assets/doh/downloads/pdf/basas/opioid-prescribing-guidelines.pdf

712. Washington State Agency Medical Directors' Group (AMDG). Interagency guideline on prescribing opioids for pain, 3rd ed. From Washington State AMDG website. 2015 Jun. http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf

750. US Food and Drug Administration. Drug safety communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women. Silver Spring, MD; 2016 Dec 14. From FDA website. https://www.fda.gov/Drugs/DrugSafety/ucm532356.htm

751. Davidson AJ, Disma N, de Graaff JC et al. Neurodevelopmental outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy (GAS): an international multicentre, randomised controlled trial. Lancet. 2016; 387:239-50. http://www.ncbi.nlm.nih.gov/pubmed/26507180?dopt=AbstractPlus

752. Sun LS, Li G, Miller TL et al. Association Between a Single General Anesthesia Exposure Before Age 36 Months and Neurocognitive Outcomes in Later Childhood. JAMA. 2016; 315:2312-20. http://www.ncbi.nlm.nih.gov/pubmed/27272582?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&artid=5316422&blobtype=pdf

753. US Food and Drug Administration. Drug safety communication: FDA approves labeling changes for use of general anesthetic and sedation drugs in young children. Silver Spring, MD; 2017 Apr 27. From FDA website. https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm

HID. Trissel LA. Handbook on injectable drugs. 17th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2013:714-21.

a. AHFS drug information 2004. McEvoy GK, ed. Lorazepam. Bethesda, MD: American Society of Hospital Pharmacists; 2004:2388-91.

b. AHFS drug information 2004. McEvoy GK, ed. Benzodiazepine general statement. Bethesda, MD: American Society of Hospital Pharmacists; 2004:2372-80.

c. Wyeth Laboratories. Ativan (lorazepam) tablets prescribing information. Philadelphia, PA; 1999 Feb.

d. Wyeth Laboratories. Ativan (lorazepam) injection prescribing information. In: Physicians’ desk reference. 55th ed. Montvale, NJ: Medical Economics Company Inc; 2001: 3344-8.

Hide